Загрузка...
Alemtuzumab by Continuous Intravenous Infusion Followed by Subcutaneous Injection Plus Rituximab in the Treatment of Patients With Chronic Lymphocytic Leukemia Recurrence
BACKGROUND: Monoclonal antibodies may be used more effectively in combination. A previous study of intravenous (iv) bolus alemtuzumab plus rituximab in patients with chronic lymphocytic leukemia (CLL) recurrence produced a response rate of 54% after a 4-week treatment period. METHODS: To optimize do...
Сохранить в:
| Опубликовано в: : | Cancer |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4476388/ https://ncbi.nlm.nih.gov/pubmed/20225334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24958 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|